Augmentation Strategies of Clozapine With Antipsychotics in the Treatment of Ultraresistant Schizophrenia

@article{Mouaffak2006AugmentationSO,
  title={Augmentation Strategies of Clozapine With Antipsychotics in the Treatment of Ultraresistant Schizophrenia},
  author={Fayçal Mouaffak and Constantin Tranulis and Rapha{\"e}l Gourevitch and Marie France Poirier and Saida Douki and Jean Pierre Oli{\'e} and Henri L{\^o}o and David Gourion},
  journal={Clinical Neuropharmacology},
  year={2006},
  volume={29},
  pages={28-33}
}
Background: Approximately 40% to 70% of neuroleptic-resistant schizophrenic patients are nonresponders to clozapine. Several clozapine augmentation strategies have come into clinical practice although often without evidence-based support. Among these strategies, the combined use of clozapine with another antipsychotic has been reported for up to 35% of patients receiving clozapine. Objective: The purposes of the present work were to (1) review the available literature on the efficacy and safety… Expand
When Clozapine Fails: Augmentation Strategies in the Management of Clozapine-Resistant Schizophrenia
TLDR
The aim of this chapter was to provide an overview of the managing strategies of clozapine-resistant schizophrenia with a particular focus on augmentation strategies aimed to improve efficacy on schizophrenia symptoms. Expand
Treatment of Clozapine Nonresponders
TLDR
Electroconvulsive therapy (ECT) is possibly the most effective augmentation strategy in patients not responding or partially responding to clozapine and require augmentation of clozAPine with another treatment strategy. Expand
Clozapine resistant schizophrenia: Newer avenues of management
  • Subho Chakrabarti
  • Medicine
  • World journal of psychiatry
  • 2021
TLDR
The options proposed include developing a clinical consensus about the augmentation strategies that are most likely to be effective and using them sequentially in patients with CRS, and newer approaches such as augmentation with long-acting antipsychotic injections or multi-component psychosocial interventions could be considered. Expand
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
TLDR
There were some significant differences between clozapine combination strategies for global and mental state (clinically significant response and change), and there were data for leaving the study early and weight gain, but no data for service utilisation and quality of life. Expand
Augmenting Clozapine Response in Treatment-Resistant Schizophrenia
Clozapine has been identified as the drug of choice in refractory or treatment-resistant schizophrenia; however, as many as 40–70% of individuals continue to demonstrate suboptimal clinical response.Expand
Is clozapine—aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?
TLDR
It is suggested that clozapine—aripiprazole is a safe and tolerable combination; however, controL trials are needed to validate the findings. Expand
Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
TLDR
Economic analyses indicated that amisulpride augmentation has the potential to be cost-effective in the short term [net saving of between £329 and £2011; no difference in quality-adjusted life-years (QALYs)] and possibly in the longer term and could have implications for the nature and frequency of safety and tolerability monitoring of clozapine augmentation with a second antipsychotic in both clinical and research settings. Expand
Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine
TLDR
More research is needed to better define outcomes in schizophrenia, the topic of treatment-resistance and more well-designed trials are required to establish true efficacy and safety of CLZ augmentation strategies. Expand
Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia
TLDR
This project is a prospective, multicentre, randomized, parallel-group, superiority trial that follow patients over a period of 12 months to generate evidence on whether it is clinically useful to combine clozapine with aripiprazole rather than with haloperidol. Expand
Aripiprazole in Addition to Clozapine in Partially Responsive Patients with Schizophrenia: A Critical Review of Case Series
The present review was conducted to ascertain whether the combination of clozapine and aripiprazole may have a clinical role in patients partially responsive to clozapine monotherapy. We conducted aExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 64 REFERENCES
Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine
TLDR
A retrospective evaluation of reports from a clinic of clozapine-treated patients whose persistent psychotic symptoms markedly lessened with the addition of pimozide is reported. Expand
Clozapine augmentation: safety and efficacy.
TLDR
From these data, the greatest risk of adverse effects seems to be associated with clozapine combined with benzodiazepines, valproate, or lithium, but no currently evaluated combination is absolutely unsafe. Expand
Risperidone augmentation of clozapine.
While effective as a single agent in a significant proportion of treatment refractory patients, clozapine is often used in combination with other medications, including classical neuroleptics (1),Expand
Combination of clozapine and amisulpride in treatment-resistant schizophrenia--case reports and review of the literature.
TLDR
The combination of amisulpride with clozapine considerably enriches the therapeutic arsenal in cases of severe schizophrenic psychoses and reduces the side effects of monotherapy. Expand
When symptoms persist: clozapine augmentation strategies.
TLDR
A synthesis of the available literature on the range and efficacy of clozapine augmentation strategies that may be used when monotherapy fails shows that current systematic efforts to enhance the treatment of patients with adjunctive therapies are worthy of being studied in carefully conducted clinical trials. Expand
Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study.
TLDR
A subgroup of patients with chronic schizophrenia may substantially benefit from sulpiride addition to clozapine, and this data indicates that this group of patients is likely to be more responsive to typical antipsychotics than the general population. Expand
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
TLDR
In this relatively brief study, the apparently increased comparative risk of agranulocytosis requires that the use of clozapine be limited to selected treatment-resistant patients. Expand
Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.
TLDR
In an open 4-week trial involving 12 treatment-resistant schizophrenic patients, the addition of risperidone to clozapine was well tolerated and produced significant reduction of symptoms, suggesting that this may be a useful clinical approach. Expand
Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
TLDR
In patients with a suboptimal response to clozapine, the addition of risperidone improved overall symptoms and positive and negative symptoms of schizophrenia and the combination appears to be safe and well tolerated. Expand
A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.
TLDR
Adjunctive risperidone treatment in schizophrenia patients partially responsive to clozapine does not significantly improve psychopathology or quality of life compared to placebo in a 6-week period. Expand
...
1
2
3
4
5
...